| Objective:To explore the effect of dapagliflozin on blood pressure,body weight and body mass index(BMI)in young,middle-aged and non-diabetic,hypertensive patients with overweight or obesity.Methods:A total of 30 young,middle-aged and non-diabetic,hypertensive patients with overweight or obesity,who were treated in the outpatient department of Cardiology of Shanxi Provincial People’s Hospital from August 2020 to June 2021 were selected and included in the study with the informed consent of the patients.They were randomly divided into control group and observation group(15 cases in each group).Both groups were treated with irbesartan and hydrochlorothiazide 150/12.5 mg once a day for 12weeks;the observation group was added dapagliflozin 10 mg once a day for 12 weeks.Strict management of lifestyle(Including healthy diet and exercise)were recommended to all the patients,After 12 weeks,the changes in blood pressure,body weight and BMI,were compared in two groups,meantime the therapeutic effect and side effect were also compared.Results:After 12 weeks treatment,blood pressure,body weight and BMI decreased significantly in both the observation group and the control group(p < 0.05),compared to the control group,the decrease of body weight and BMI in the Observation Group was more significant(p < 0.05),although the reduction of blood pressure in the observation group had much lower tendency than that in the control group,but the difference was not statistically significant(p > 0.05).There were no adverse events such as hypotension,hypoglycemia and urinary tract infection in 2 groups.Conclusion:After 12 weeks of dapagliflozin(10 mg once a day)in young,middle-aged and non-diabetic,hypertensive patients with overweight or obesity,there was no significant difference in the anti-hypertensive effect compared to the control group,but a further lower reduced tendency in blood pressure,and significant reduction of body weight,BMI and fasting blood-glucose were observed. |
PDF Full Text Request